Macrocyclic analogs and methods of their use and preparation
AssigneeEisai Co., Ltd.
InventorsBruce A. Littlefield, Monica H. Palme, Boris M. Seletsky, Murray J. Towle, Melvin J. Yu, Wanjun Zheng
Life of this patent
Estimating the term…
Abstract
The invention provides halichondrin analogs having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity, and methods of identifying agents that induce a sustained mitotic block in a cell after transient exposure of the cell to the agents.
Claims21
A compound having the formula:
- wherein A is a C1-6 saturated or C2-6 unsaturated hydrocarbon skeleton, said skeleton being unsubstituted or having between 1 and 10 substituents, inclusive, independently selected from cyano, halo, azido, oxo, and Q1;
- each Q1 is independently selected from OR1, SR1, SO2R1, OSO2R1, NR2R1, NR2(CO)R1, NR2(CO)(CO)R1, NR4(CO)NR2R1, NR2(CO)OR1, (CO)OR1, O(CO)R1, (CO)NR2R1, and O(CO)NR2R1;
- each of R1, R2, R4, R5, and R6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C6-10 aryl, C6-10 haloaryl, C6-10 hydroxyaryl, C1-3 alkoxy-C6 aryl, C6-10 aryl-C1-6 alkyl, C1-6 alkyl-C6-10 aryl, C6-10 haloaryl-C1-6 alkyl, C1-6 alkyl-C6-10 haloaryl, (C1-3 alkoxy-C6 aryl)-C1-3 alkyl, C2-9 heterocyclic radical, C2-9 heterocyclic radical-C1-6 alkyl, C2-9 heteroaryl, and C2-9 heteroaryl-C1-6 alkyl;
- each of D and D′ is independently selected from R3 and OR3, wherein R3 is H, C1-3 alkyl, or C1-3 haloalkyl;
- n is 0 or 1;
- E is R5 or OR5;
- G is O, S, CH2, or NR6;
- each of J and J′ is independently H, C1-6 alkoxy, or C1-6 alkyl;
- or J and J′ taken together are ═CH2 or —O-(straight or branched C1-5alkylene)-O—;
- Q is C1-3 alkyl;
- T is ethylene or ethenylene, optionally substituted with (CO)OR7, where R7 is H or C1-6 alkyl;
- each of U and U′ is independently H, C1-6 alkoxy, or C1-6 alkyl;
- or U and U′ taken together are ═CH2 or —O-(straight or branched C1-5alkylene)-O—;
- X is H or C1-6 alkoxy;
- each of Y and Y′ is independently H or C1-6 alkoxy;
- or Y and Y′ taken together are ═O, ═CH2, or —O-(straight or branched C1-5alkylene)-O—;
- and
- each of Z and Z′ is independently H or C1-6 alkoxy;
- or Z and Z′ taken together are ═O, ═CH2, or —O-(straight or branched C1-5alkylene)-O—;
- or a pharmaceutically acceptable salt thereof.
The compound of the following structure
The compound of the following structure
- and pharmaceutically acceptable salts thereof.
A method for identifying an agent that induces a sustained mitotic block in a cell after transient exposure of said cell to said agent, said method comprising the steps of:
- (a) incubating a first cell sample with a predetermined concentration of a test compound for a time interval between that sufficient to empty the G1 population and that equivalent to one cell cycle;
- (b) substantially separating said test compound from said first cell sample;
- (c) incubating said first sample in media free of said test compound for a time interval sufficient to allow at least 80% of the cells released from the mitotic block induced by a highly reversible mitotic inhibitor to complete mitosis and return to the G1 phase;
- and
- (d) measuring the percentage of transiently-exposed cells from step (c) that have completed mitosis and returned to the G1 phase.
Dependencies are inferred from the claim text.